罗氏将完成15亿美元收购美国生物制药公司Poseida

智通财经01-08

智通财经APP获悉，罗氏(RHHBY.US)周三表示，计划完成对美国生物制药公司Poseida Therapeutics(PSTX.US)的收购。据了解，Poseida专注于开发多种类型癌症的复杂免疫细胞疗法。罗氏表示，已接受支付Poseida近6500万股股份，相当于该公司股票的66%，股东以每股9美元的价格出价，并额外支付每股高达4美元的或有付款。考虑到这一因素，该交易的价值将高达约15亿美元...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2501145617?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-08 15:52","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2501145617","market":"us","top_or_hot":-1,"title":"罗氏将完成15亿美元收购美国生物制药公司Poseida","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，罗氏(RHHBY.US)周三表示，计划完成对美国生物制药公司Poseida Therapeutics(PSTX.US)的收购。据了解，Poseida专注于开发多种类型癌症的复杂免疫细胞疗法。罗氏表示，已接受支付Poseida近6500万股股份，相当于该公司股票的66%，股东以每股9美元的价格出价，并额外支付每股高达4美元的或有付款。考虑到这一因素，该交易的价值将高达约15亿美元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010815573195fc8d21&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>罗氏将完成15亿美元收购美国生物制药公司Poseida</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n罗氏将完成15亿美元收购美国生物制药公司Poseida\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 15:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010815573195fc8d21&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，罗氏(RHHBY.US)周三表示，计划完成对美国生物制药公司Poseida Therapeutics(PSTX.US)的收购。据了解，Poseida专注于开发多种类型癌症的复杂免疫细胞疗法。罗氏表示，已接受支付Poseida近6500万股股份，相当于该公司股票的66%，股东以每股9美元的价格出价，并额外支付每股高达4美元的或有付款。考虑到这一因素，该交易的价值将高达约15亿美元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010815573195fc8d21&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010815573195fc8d21&s=b","article_id":"2501145617","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010815573195fc8d21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2501145617","pubTimestamp":1736322752,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"据了解，Poseida专注于开发多种类型癌症的复杂免疫细胞疗法。罗氏表示，已接受支付Poseida近6500万股股份，相当于该公司股票的66%，股东以每股9美元的价格出价，并额外支付每股高达4美元的或有付款。罗氏称，在收购中，Poseida或罗氏不拥有的所有Poseida股份将转换为每股获得相同对价的权利。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","PSTX":"Poseida Therapeutics, Inc."},"translate_title":"Roche to complete $1.5 billion acquisition of US biopharmaceutical company Poseida","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSTX":0.9},"content_text":"智通财经APP获悉，罗氏(RHHBY.US)周三表示，计划完成对美国生物制药公司Poseida Therapeutics(PSTX.US)的收购。据了解，Poseida专注于开发多种类型癌症的复杂免疫细胞疗法。罗氏表示，已接受支付Poseida近6500万股股份，相当于该公司股票的66%，股东以每股9美元的价格出价，并额外支付每股高达4美元的或有付款。考虑到这一因素，该交易的价值将高达约15亿美元。该收购于去年11月宣布，是罗氏为弥补不断下降的肿瘤药物销售而扩大其研发管线的最新举措。罗氏周三表示：“今天晚些时候，罗氏打算完成对Poseida的收购……无需投票或召开Poseida股东大会。”罗氏称，在收购中，Poseida或罗氏不拥有的所有Poseida股份将转换为每股获得相同对价的权利。Poseida将成为罗氏的全资子公司，为后者增加所谓的同种异体CAR-T细胞疗法，该疗法使用转基因免疫细胞攻击癌症细胞或治疗自身免疫疾病。Poseida还致力于针对实体瘤和自身免疫性疾病的CAR-T项目。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501145617","isCrawlerRequest":true}